Post-MERINO trial: Any role for piperacillin-tazobactam in treating bloodstream infections caused by extended-spectrum beta-lactamase producing Enterobacteriaceae?

Int J Antimicrob Agents. 2019 May;53(5):557-558. doi: 10.1016/j.ijantimicag.2019.03.007. Epub 2019 Mar 14.

Author

Maroun M Sfeir¹

Affiliation

¹ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA; Department of Pathology, Harvard Medical School, Boston, MA, USA. Electronic address: msfeir@mgh.harvard.edu.

PMID: 30880227
DOI: 10.1016/j.ijantimicag.2019.03.007

No abstract available

Publication types

Editorial

MeSH terms

Anti-Bacterial Agents / administration & dosage*
Enterobacteriaceae Infections / drug therapy*
Escherichia coli / enzymology*
Escherichia coli / isolation & purification
Humans
Klebsiella pneumoniae / enzymology*
Klebsiella pneumoniae / isolation & purification
Multicenter Studies as Topic
Piperacillin, Tazobactam Drug Combination / administration & dosage*
Randomized Controlled Trials as Topic
Sepsis / drug therapy
Survival Analysis
Treatment Outcome
beta-Lactamase Inhibitors / administration & dosage*
beta-Lactamases / metabolism*

Substances

Anti-Bacterial Agents
beta-Lactamase Inhibitors
Piperacillin, Tazobactam Drug Combination
beta-Lactamases